Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

The approval of Yeztugo is a momentous step in improving PrEP options available for people vulnerable to contracting ...

Gilead and its partners' efforts to distribute generic lenacapavir could be derailed by cuts in international aid budgets ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

The World Health Organization (WHO) on Monday recommended countries to use the twice-a-year lenacapavir injection as an add ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at ...

Yeztugo (lenacapavir) is the first and only injectable drug that can prevent HIV acquired through sexual contact with just two injections a year. Clinical trials showed that the medication ...

Lenacapavir, marketed under the brand name Yeztugo, has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents making it functionally akin to a ...

Foster City-headquartered Gilead Sciences Inc, a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the US FDA has approved ...